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South African Indians (originally migrants 
from South Asia) have the highest rates of 
cardiovascular disease and diabetes in the 
country – and a fascinating contributor 
may be that their blood vessels are narrower 
than those of other race groups. Coronary 
angiograms and postmortem studies reveal 
this little known fact, according to Dr 
Alexander T Cohen, honorary consultant 
vascular physician at Kings College Hospital 
in London, who cautioned that the high 
diabetes rates were primarily responsible 
for the cardiovascular elevation.
This emerged in an interview with Cohen 
who recently completed a lecture tour of 
South Africa updating doctors, pharmacists 
and nurses on a ground-breaking new oral 
therapy for venous thrombo-embolism 
(VTE). Cohen is also an epidemiologist 
involved in clinical work, designing, 
managing and analysing clinical trials from 
phase 1 to 1V, and both chairs and serves 
on several international steering committees 
for multicentre trials, and epidemiological 
and pharmaco-economic studies. The 
nugget about lower-calibre blood vessels 
in Indians emerged when he was asked his 
opinion on why the highest rates of heart 
and blood vessel disease in South Africa 
occur in this community (followed by the 
coloured community, with the white and 
black communities having the lowest and 
most similar rates). 
He also put the dramatically differing 
patterns between the white and black local 
populations (in spite of their having similar 
rates of disease) down to research skewed 
by healthcare inequities. Seemingly, the white 
population predominantly has a pattern of 
deaths due to heart attacks, while the black 
population predominantly has a pattern of 
deaths due to stroke, heart muscle disease 
and heart disease due to high blood pressure. 
‘What you may possibly be seeing in some 
centres in South Africa is that a black person 
comes with a swollen leg and the doctor is 
not suspecting venous thrombosis and hence 
says take an aspirin or anti-inflammatory and 
they go. This is because the level of clinical 
suspicion or pretest probability may be low in 
this racial group. However, this is not borne 
out by research in African Americans where 
VTE rates are similar or higher than whites. 
In contrast, if a white person comes in and 
is seen in private the clinical suspicion is 
higher, the threshold for investigation is likely 
to be lower and hence they get a leg scan 
and the DVT is diagnosed, or in the case of 
respiratory symptoms they are sent for a lung 
scan.’ His comments were greeted with some 
alarm by local public sector vascular surgeons 
and haematologists afraid that they would 
appear uncaring along racial lines, but Cohen 
was referring to the overall healthcare system 
(split between medically insured and medically 
uninsured) where glaring racial inequities in 
access and treatment persist, particularly at 
primary healthcare level from where public 
sector patients are referred upwards.
 Referring to the Indian vascular anomaly, 
he said Indians were genetically Caucasian 
and varied little from the Western European 
population. Indians, Pakistanis, Bangladeshis 
and Sri-Lankans had the highest rates of 
diabetes and lipid abnormalities, and high rates 
of cardiovascular disease (in particular arterial 
and venous disease). ‘Interestingly when you 
do the investigations, the width of their vessels 
is somewhat narrower. It’s potentially a big 
problem. You see this in coronary angiograms. 
The blood vessels are just not as wide. The 
things that make it different in the rate of 
venous thrombosis are much broader than 
what makes it different in arterial thrombosis. 
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In venous clots (deep vein thrombosis (DVT)), 
however, it’s a completely different set of 
risk factors,’ he added. The aforementioned 
factors were present but very weak. Rather, 
immobilisation (especially after a stroke), 
all types of surgery, infections, heart failure, 
respiratory failure, cancer, rheumatological 
disorders and oral contraceptives came to the 
fore with DVT. If all of these were eliminated, 
then blood tests often revealed a congenital 
predisposition, while flying for more than four 
hours was a significant risk.
Doctors missing VTE – Cohen
Cohen believes research showing that heart 
and blood vessel disease claimed 195 South 
African lives per day between 1997 and 2004 
actually underestimates the true situation. This 
is because for every blood clot diagnosis prior 
to death another two are found on autopsy 
that were not suspected. He believes that 
the associated morbidity and mortality are 
‘significantly elevated’ because of HIV/AIDS 
and tuberculosis. Cohen said blood clots were 
easily and often misdiagnosed. He said the 
chronic nature of VTE and its complications, 
such as post-thrombotic syndrome and 
pulmonary hypertension, generated a 
considerable health burden. In the absence 
of thromboprophylaxis, DVT developed in 
40 - 60% of patients undergoing total knee 
replacement or total hip replacement and in 10 
- 40% of medical and general surgery patients. 
After coronary heart disease and stroke, VTE 
was the third most common cardiovascular 
disease, with more than a third of cases 
representing recurrent VTE. The number of 
VTE deaths in Europe was three times greater 
than the combined number of deaths from 
breast cancer, AIDS and road traffic accidents. 
A VTE impact assessment group in Europe 
estimating the total mortality burden of VTE 
in France, Germany, Italy, Spain, Sweden 
and the UK (12% of all deaths), found that 
59% occurred after undiagnosed pulmonary 
embolism. Intrinsic risk factors included 
gender, age and malignancy, while extrinsic 
risk factors included recent surgery or trauma.
New oral therapy a treatment boon
Cohen said the new oral therapy for VTE, 
rivaroxaban (in use for nearly six months 
in the UK, a year in Canada and Germany 
and nearly five months in Australia), was 
ground breaking. Whereas injected heparins 
(like enoxaparin and dalteparin) and oral 
warfarin resulted in an increased chance of 
cerebral bleeding, rivaroxaban was both safer 
and reduced the incidence of all major and 
critical bleeding. Rivaroxaban removed the 
need for heparin injections, the regular blood 
tests and the monitoring needed with the 
traditional duo of drug treatments; it was 
also less expensive and vastly easier for the 
physician to manage. A big advantage was that 
patients did not have to have their warfarin 
levels monitored by INR on a regular basis. 
The Federal Drug Administration (FDA) in 
the USA recently approved the drug which 
Cohen predicted would create ‘a sea of change 
in the way we practice’.
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